[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573414":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":11,"studyPopulation":11,"armGroups":32,"interventions":38,"overallOfficials":11,"centralContacts":43,"locations":49,"responsibleParty":66,"collaborators":11,"id":68,"slug":11,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":11,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":85,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Epigenic Therapeutics, Inc","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs",null,"From Baseline through to Day 28 postdose",[14,16,18,20],{"measure":15,"description":11,"timeFrame":12},"Evaluation of maximum observed concentration (Cmax)",{"measure":17,"description":11,"timeFrame":12},"Evaluation of maximum observed concentration (tmax)",{"measure":19,"description":11,"timeFrame":12},"Evaluation of terminal elimination half-life (t1\u002F2)",{"measure":21,"description":11,"timeFrame":22},"HBsAg","From Baseline through to Day 365 postdose",[24],{"measure":25,"description":11,"timeFrame":22},"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"NA","SINGLE_GROUP","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":11},"NONE",[33],{"label":34,"type":35,"description":11,"interventionNames":36},"EPI-003","EXPERIMENTAL",[37],"Drug: EPI-003",[39],{"type":40,"name":34,"description":41,"armGroupLabels":42,"otherNames":11},"DRUG","Intravenous (IV) infusion.",[34],[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"Feng Epigenic Therapeutics Clinical Trials","CONTACT","86-17621694653","clinical@epigenictx.com",[50],{"facility":51,"status":11,"city":52,"state":11,"zip":11,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Renji Hospital, Shanghai Jiao Tong University School of Medicine","Shanghai","China","CN",{"type":56,"coordinates":57},"Point",[58,59],121.45806,31.22222,{"lat":59,"lon":58},[62],{"name":63,"role":46,"phone":64,"phoneExt":11,"email":65},"YANG","+86 18201797677","yang_taihua@126.com",{"type":67,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100573414",false,"NCT06745973","An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B","Inclusion Criteria:\n\n1. Be between 18 and 65 years of age, inclusive, at the time of signing the informed consent form;\n2. Confirmed diagnosis of CHB;\n3. Received a stable dose of NA therapy for ≥ 6 months prior to screening and plan to continue receiving the same dose for the duration of the study\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of liver cancer or cirrhosis;\n2. Combination of other major diseases; 3 Pregnant or lactating females.","ALL","18 Years","65 Years",{"count":77,"type":78},20,"ESTIMATED","INTERVENTIONAL",[81],"EARLY_PHASE1","This study is an open-label, 2-Part (Single Ascending Dose \\[Part 1\\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself.",[84],"Chronic Hepatitis B","NOT_YET_RECRUITING","2024-12-18",{"date":88,"type":89},"2024-12-24","ACTUAL",{"date":91,"type":78},"2024-12-20",{"date":93,"type":78},"2026-12-31",{"name":5,"class":6},1]